Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Chugai Pharmaceutical Co Ltd's Anti-Cancer Agent "Tarceva" Obtains Approval for Additional Indication (First Line Therapy) of Non-Small Cell Lung Cancer with EGFR Mutations-Yakuji Nippo


Friday, 14 Jun 2013 08:00pm EDT 

Yakuji Nippo reported that Chugai Pharmaceutical Co Ltd has obtained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) on June 14, 2013, for the additional indication of "chemotherapy-naive, unresectable, recurrent/advanced non-small cell lung cancer (NSCLC) with EGFR mutations" for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, "Tarceva Tablet 25mg, 100mg and 150mg" (generic name: erlotinib hydrochloride). 

Company Quote

3275.0
-20.0 -0.61%
2:00am EDT